Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Initial clinical trial and pharmacokinetics of Thymitaq (AG337) by 10-day continuous infusion in patients with advanced solid tumors.

Creaven PJ, Pendyala L, Meropol NJ, Clendeninn NJ, Wu EY, Loewen GM, Proefrock A, Johnston A, Dixon M.

Cancer Chemother Pharmacol. 1998;41(2):167-70.

PMID:
9443631
2.

Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days.

Hughes AN, Rafi I, Griffin MJ, Calvert AH, Newell DR, Calvete JA, Johnston A, Clendeninn N, Boddy AV.

Clin Cancer Res. 1999 Jan;5(1):111-8.

4.

A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.

Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ.

Clin Cancer Res. 1999 Sep;5(9):2381-91.

5.

Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.

Morgan RJ Jr, Newman EM, Doroshow JH, McGonigle K, Margolin K, Raschko J, Chow W, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Carroll M, Vasilev S, Akman S, Coluzzi P, Wagman L, Longmate J, Paz B, Yen Y, Klevecz R.

Cancer Res. 1998 Jul 1;58(13):2793-800.

6.

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.

Jodrell DI, Bowman A, Rye R, Byrne B, Boddy A, Rafi I, Taylor GA, Johnston A, Clendeninn NJ.

Br J Cancer. 1999 Feb;79(5-6):915-20.

7.

A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.

Hidalgo M, Rodriguez G, Kuhn JG, Brown T, Weiss G, MacGovren JP, Von Hoff DD, Rowinsky EK.

Clin Cancer Res. 1998 Nov;4(11):2763-70.

8.
9.

A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.

Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K, Vermorken JB.

Anticancer Drugs. 2007 Jun;18(5):587-95.

PMID:
17414628
10.

Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.

Rees C, Beale P, Trigo JM, Mitchell F, Jackman A, Smith R, Douglass E, Judson I.

Clin Cancer Res. 2003 Jun;9(6):2049-55.

11.

A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.

Pinguet F, Culine S, Bressolle F, Astre C, Serre MP, Chevillard C, Fabbro M.

Clin Cancer Res. 2000 Jan;6(1):57-63.

12.

A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.

Schwartz G, Johnson TR, Goetz A, Burris H, Smetzer L, Lampkin T, Sailstad J, Hohneker JA, Von Hoff DD, Rowinsky EK.

Clin Cancer Res. 2001 Jul;7(7):1901-11.

13.

A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion.

Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP Jr.

Cancer Chemother Pharmacol. 2000;46(4):319-28.

PMID:
11052630
14.

Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.

Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S.

Invest New Drugs. 2007 Feb;25(1):85-94. Epub 2006 Sep 7.

PMID:
16957834
15.

A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.

Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ.

Clin Cancer Res. 2001 Dec;7(12):3912-9.

17.

Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.

Rafi I, Boddy AV, Calvete JA, Taylor GA, Newell DR, Bailey NP, Lind MJ, Green M, Hines J, Johnstone A, Clendeninn N, Calvert AH.

J Clin Oncol. 1998 Mar;16(3):1131-41.

PMID:
9508200
18.

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.

Hurwitz HI, Cohen RB, McGovren JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T.

Cancer Chemother Pharmacol. 2007 Jan;59(1):139-47. Epub 2006 Jul 4.

PMID:
16819636
19.

[Phase I study of raltitrexed (ZD-1694)].

Horikoshi N, Aiba K, Fukuoka M, Akazawa S, Sakata Y, Furuse K, Kanamaru R, Kudoh S, Konishi T, Kurihara M, Niitani H, Furue H, Tsukagoshi S, Taguchi T, Yoshida S, Ota K, Kotake T, Wakui A.

Gan To Kagaku Ryoho. 1998 Nov;25(13):2075-84. Japanese.

PMID:
9838910
20.

Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study.

Dueland S, Aamdal S, Lind MJ, Thomas H, Sandvold ML, Gaullier JM, Rasch W.

Acta Oncol. 2009;48(1):137-45. doi: 10.1080/02841860802183620.

PMID:
18607882

Supplemental Content

Support Center